Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)

Vera Gorbunova, J. Thaddeus Beck, Ralf Dieter Hofheinz, Pilar Garcia-Alfonso, Marina Nechaeva, Antonio Cubillo Gracian, Laszlo Mangel, Elena Elez Fernandez, Dustin A. Deming, Ramesk K Ramanathan, Alison H. Torres, Danielle Sullivan, Yan Luo, Jordan D. Berlin

Research output: Contribution to journalComment/debate

Abstract

The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Original languageEnglish (US)
JournalBritish journal of cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Colorectal Neoplasms
Placebos
Neoplasms
veliparib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Correction : A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z). / Gorbunova, Vera; Beck, J. Thaddeus; Hofheinz, Ralf Dieter; Garcia-Alfonso, Pilar; Nechaeva, Marina; Gracian, Antonio Cubillo; Mangel, Laszlo; Fernandez, Elena Elez; Deming, Dustin A.; Ramanathan, Ramesk K; Torres, Alison H.; Sullivan, Danielle; Luo, Yan; Berlin, Jordan D.

In: British journal of cancer, 01.01.2019.

Research output: Contribution to journalComment/debate

Gorbunova, Vera ; Beck, J. Thaddeus ; Hofheinz, Ralf Dieter ; Garcia-Alfonso, Pilar ; Nechaeva, Marina ; Gracian, Antonio Cubillo ; Mangel, Laszlo ; Fernandez, Elena Elez ; Deming, Dustin A. ; Ramanathan, Ramesk K ; Torres, Alison H. ; Sullivan, Danielle ; Luo, Yan ; Berlin, Jordan D. / Correction : A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z). In: British journal of cancer. 2019.
@article{1183fd9c77674aca9e810daa9e433e95,
title = "Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)",
abstract = "The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be accessed via a link at the top of the paper.",
author = "Vera Gorbunova and Beck, {J. Thaddeus} and Hofheinz, {Ralf Dieter} and Pilar Garcia-Alfonso and Marina Nechaeva and Gracian, {Antonio Cubillo} and Laszlo Mangel and Fernandez, {Elena Elez} and Deming, {Dustin A.} and Ramanathan, {Ramesk K} and Torres, {Alison H.} and Danielle Sullivan and Yan Luo and Berlin, {Jordan D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41416-019-0528-0",
language = "English (US)",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Correction

T2 - A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)

AU - Gorbunova, Vera

AU - Beck, J. Thaddeus

AU - Hofheinz, Ralf Dieter

AU - Garcia-Alfonso, Pilar

AU - Nechaeva, Marina

AU - Gracian, Antonio Cubillo

AU - Mangel, Laszlo

AU - Fernandez, Elena Elez

AU - Deming, Dustin A.

AU - Ramanathan, Ramesk K

AU - Torres, Alison H.

AU - Sullivan, Danielle

AU - Luo, Yan

AU - Berlin, Jordan D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

AB - The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

UR - http://www.scopus.com/inward/record.url?scp=85069717633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069717633&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0528-0

DO - 10.1038/s41416-019-0528-0

M3 - Comment/debate

C2 - 31350526

AN - SCOPUS:85069717633

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -